Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer

Inclusion Criteria

• •DISEASE CHARACTERISTICS:
• •Histologically confirmed adenocarcinoma of the prostate
• •Relapsed disease after definitive local therapy, as documented only by a rise in prostate-specific antigen (PSA)
• •* Experienced PSA relapse after definitive local therapy
• •* Rising PSA (≥ 1.0 ng/mL after nadir \< 1.0 ng/mL)
• •* PSA increase of ≥ 0.3 ng/mL (increase occurred between 2 separate measurements taken ≥ 4 weeks apart)
• •* The first of these two PSA values must rise above a previously recorded post-therapy nadir value
• •Ineligible for curative therapy
• •No clinical evidence of local recurrence (i.e., palpable induration or mass in the prostatic fossa) other than PSA elevation
• •No evidence of palpable disease in the prostatic bed
• •No metastatic disease (M0)
• •* No non-nodal (\> N1) metastasis
• •* No evidence of osseous metastasis on bone scan within the past 28 days
• •PATIENT CHARACTERISTICS:
• •Age
• •Over 18
• •Performance status
• •ECOG 0-1
• •Life expectancy
• •At least 1 year
• •Hematopoietic
• •Platelet count ≥ 30,000/mm\^3
• •Absolute neutrophil count ≥ 1,000/mm\^3
• •Hepatic
• •No known hepatitis B or C positivity
• •Renal
• •Creatinine clearance ≥ 30 mL/min
• •Immunologic
• •No known human T-cell lymphotropic virus positivity
• •No hypersensitivity to bortezomib, boron, or mannitol
• •No known HIV 1 or 2 positivity
• •No active, ongoing bacterial, viral, or fungal infection
• •Other
• •Fertile patients must use effective contraception
• •No peripheral neuropathy ≥ grade 2
• •No other disease, condition, or social or geographic constraint that would preclude study participation
• •No other malignancy within the past 5 years except basal cell or squamous cell skin cancer
• •PRIOR CONCURRENT THERAPY:
• •Biologic therapy
• •Not specified
• •Chemotherapy
• •No concurrent chemotherapy
• •Endocrine therapy
• •See Disease Characteristics
• •At least 6 months since prior hormonal therapy combined with radiation therapy as definitive therapy
• •Neoadjuvant hormonal therapy prior to definitive therapy (e.g., surgery, radiation therapy, brachytherapy, or cryoablation) allowed
• •No other concurrent hormonal therapy
• •Radiotherapy
• •See Disease Characteristics
• •More than 12 months since prior radioactive seed therapy
• •No concurrent radiotherapy
• •Surgery
• •See Disease Characteristics
• •More than 4 weeks since prior surgery
• •No concurrent surgery
• •Other
• •No concurrent second-line herbal preparations, including PC-SPES
• •No other concurrent investigational agents